Home > Boards > US Listed > Biotechs > Durect (DRRX)

NSDQ has 435,000 for sale on the ask

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
turning stone Member Profile
 
Followed By 6
Posts 382
Boards Moderated 0
Alias Born 03/24/09
160x600 placeholder
DURECT to Present at the Stifel 2019 Health Care Conference PR Newswire (US) - 11/15/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 5:08:19 PM
DURECT Corporation Announces Positive Results from the Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis Patients in ... PR Newswire (US) - 11/12/2019 8:45:00 AM
DURECT to Host Key Opinion Leader Call on DUR-928 Phase 2a Alcoholic Hepatitis Study Results PR Newswire (US) - 11/6/2019 5:47:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/5/2019 3:37:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/4/2019 4:21:37 PM
DURECT Corporation Announces Third Quarter 2019 Financial Results and Update of Programs PR Newswire (US) - 11/4/2019 4:05:00 PM
DURECT Corporation to Announce Third Quarter 2019 Financial Results and Provide Business Update on November 4 PR Newswire (US) - 10/30/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/21/2019 1:00:03 PM
DURECT Announces DUR-928 Phase 2a Alcoholic Hepatitis Study Results Selected for Late-Breaking Oral Presentation at The Liver... PR Newswire (US) - 10/21/2019 10:12:00 AM
DURECT to Present at Two Upcoming NASH Investor Conferences PR Newswire (US) - 10/17/2019 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/7/2019 3:30:55 PM
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Ph... PR Newswire (US) - 10/7/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/2/2019 3:31:06 PM
DURECT Announces FDA Advisory Committee Meeting to Review POSIMIRĀ® for the Treatment of Post-Surgical Pain PR Newswire (US) - 10/2/2019 8:00:00 AM
DURECT to Present at the 2019 Cantor Fitzgerald Global Health Care Conference PR Newswire (US) - 9/26/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 10:48:26 AM
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis PR Newswire (US) - 9/17/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 1:37:50 PM
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Ut... PR Newswire (US) - 9/9/2019 9:29:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/6/2019 6:01:44 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/5/2019 2:44:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/4/2019 5:50:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 9/4/2019 5:28:35 PM
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright PR Newswire (US) - 9/4/2019 8:00:00 AM
turning stone   Tuesday, 09/17/19 11:00:08 AM
Re: None
Post # of 897 
NSDQ has 435,000 for sale on the ask @ $2.00/share some one please buy them so we can continue to move up. Very nice PR this morning and more to keep coming through the end of the year.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist